Female Stress Urinary Incontinence Clinical Trial
Official title:
Treatment of Stress Urinary Incontinence Via Smartphone
The purpose of this study is to determine whether treatment of stress urinary incontinence via smartphone is effective.
Female urinary incontinence is very common and affects up to one fourth of grownup women. It
may reduce quality of life for those affected and costs for society are high. The most
common type of urinary incontinence is stress urinary incontinence (SUI), i.e leakage when
coughing, sneezing or jumping.
The recommended first line treatment is pelvic floor muscle training (PFMT)which leads to
improvement or cure in two-thirds of patients. In addition, life style changes, such as
weight loss when obese, smoking cessation and reduction of fluid intake if high is
recommended.
There is a need for new , flexible and easily accessible treatment programmes for female
urinary incontinence. In our previous study, we compared two treatment programmes for SUI
without face-to-face contact: one internet based and one sent by post, both based on three
months of PFMT. In this randomized controlled trial of 250 women aged 18-70 years, we found
highly significant improvements (p<0.001) with large effect sizes (>0,8)concerning primary
outcomes (symptoms and quality of life scores) but no significant differences between
groups. Compared with the postal group, more participants in the internet group perceived
they were much or very much improved (40.9% vs 26.5%, p<0.01, reported reduced usage of
incontinence aids (59.5% vs 41.4%, p=0.02) and were satisfied with the treatment programme
(84.8% vs 62.9%, p<0.001).
The selling of smartphones is increasing rapidly. About 75% of all cellphones sold in Sweden
today are smartphones. Two million adults in Sweden have a smartphone. Many smartphone
owners have at least one health app on their phone. Exercise, diet, and weight apps are the
most popular types.
From our previous experience of an Internet-based programme, we have developed a treatment
program designed for smartphone. The effect of the treatment programme will be evaluated
after three months by comparing the effect in the "smartphone group" with the effect in the
"waiting group".
Participants are consecutively recruited through our website. They answer an online
screening survey with automated immediated response for initial screening of eligibility
criteria. Informed consent and leakage diary (number of episodes of urinary leakage during
48 hours) are sent by post. After that, they answer a web questionnaire and finally they are
interviewed by a researcher to confirm the diagnosis SUI and to ascertain that the patient
is well informed of the study procedure.
Women are then randomized to either of the two groups. Women in the smartphone group get a
smartphone application for iphone or android. Follow-up after three months with a web
questionnaire and a leakage diary. After that the waiting group get their smartphone
application.
We aim to recruit 120 women aged 18 and older via our website www.tät.nu. In the power
calculation we assume that the improvement in the symptom score (ICIQ UI SF) and the QOL
score (ICIQ luts QOL)in the smartphone group will be similar to the improvement we found in
the postal group in our previous study. We also assume that the waiting group will improve
in some extent.
To detect a difference between groups, power 80%, 2-side test and significance 0,05, group
size as follow
ICIQ UI SF smartphone group improves 2.9 (SD3,1) and waiting group 1,0 (SD2,0); 30 in each
group
ICIQ luts QOL Smartphone group improves 4.6 (SD6,7) and waiting group 2.0(SD3.0), 35 in each
group
PGI (patient´s global impression of improvement). 26,5% improves much or very much
(smartphone) and 4% (waiting group):39 in each group
We expect a drop out rate of 33% and thus need approximately 120 persons, 60 in each group.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05534269 -
Stress Urinary Incontinence Study to Assess Safety and Efficacy of Muvon's Muscle Precursor Cell Therapy
|
Phase 2 | |
Completed |
NCT02023502 -
Proteomic Pattern in Female Stress Urinary Incontinence: a Pilot Study
|
||
Completed |
NCT01699425 -
Multicentric Comparative Randomized Study of the Single-incision Sling Ajust® Versus Suburethral Transobturator Slings.
|
N/A | |
Completed |
NCT02418299 -
Er:YAG Laser Treatment for Female Stress and Mixed Urinary Incontinence (IncontiLase)
|
N/A | |
Completed |
NCT01094353 -
A Comparative Study Minisling Versus Transobturator (TOT)Sling
|
Phase 4 | |
Completed |
NCT00910338 -
Efficacy and Safety of Extracorporeal Biofeedback
|
N/A | |
Completed |
NCT01290796 -
Clinical Evaluation of Ajustâ„¢ in Stress Urinary Incontinence
|
N/A | |
Recruiting |
NCT04131387 -
The Safety and Efficacy of Micro-energy Ultrasound Therapy in the Treatment of Female Stress Urinary Incontinence
|
N/A | |
Not yet recruiting |
NCT02981654 -
Safety and Efficacy of Carbone Dioxide (CO2) Laser System in Treatment of Female Stress Urinary Incontinence.
|
N/A | |
Completed |
NCT01032265 -
Web-based Management of Female Stress Urinary Incontinence
|
N/A |